Uppsala, Sweden - Juni 14, 2021 - Orexo's partner, Gesynta Pharma, today announces that more than half of the patients in the ongoing phase II study of the drug candidate OX-MPI (GS-248) have been recruited. Gesynta Pharma, who owns all the rights to OX-MPI (GS-248), aims to develop a treatment for systemic sclerosis. Top-line data is expected in Q1 2022. In parallel an IND (Investigational New Drug Application) has been submitted to the US Food & Drug Administration (FDA).

Systemic sclerosis, a debilitating autoimmune disease that causes serious damage to the Microvasculature. The purpose of this study is to investigate the safety of OX-MPI (GS-248) and its efficacy on Raynaud's phenomenon and peripheral blood flow in the patient group. The study includes approximately 80 patients and the results will serve as a basis for future clinical trials in systemic sclerosis and potentially other inflammatory diseases.

For more information, please read Gesynta Pharma´s press release which is attached.

Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
Email: ir@orexo.com

Attachments

  • Original document
  • Permalink

Disclaimer

Orexo AB published this content on 14 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2021 12:39:04 UTC.